Skip to main content

Table 2 AMACR and CK20 expression in urothelial carcinoma in situ and non-neoplastic urothelium

From: Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?

   Positive Partial positive Negative Mean intensity
CIS with IHC (n = 22) AMACR 16/22 (73%) 0/22 (0%) 6/22 (27%) 2.4
CK20 21/22 (95%) 0/22 (0%) 1/22 (5%) 3.0
Non-neoplastic with IHC (n = 30) AMACR 0/30 (0%) 1/30 (3%) 29/30 (97%) 2.0
CK20 5/30 (17%) 1/30 (3%) 24/30 (80%) 2.7
CIS without IHC (n = 20) AMACR 20/20 (100%) 0/20 (0%) 0/20 (0%) 2.1
  1. CIS, Carcinoma in situ; IHC, Immunohistochemistry